ArticlePharmaceutical research2026
Population Pharmacokinetics of Voriconazole in Patients Receiving Extracorporeal Membrane Oxygenation.
Article in Pharmaceutical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeTo characterize the population pharmacokinetics (PPK) of voriconazole (VRC) in critically ill patients receiving extracorporeal membrane oxygenation (ECMO) and to identify factors contributing to pharmacokinetic (PK) variability to providing a scientific basis for the individualized and rational use of VRC.
methodsBlood samples were collected 30 min before dosing and at 0.5, 1, 2, 4, 6 and 8 h after dosing. A PPK model was developed using nonlinear mixed effects modeling (NONMEM) and evaluated for stability and predictive performance. Based on the final model, Monte Carlo Simulations (MCS) were conducted to estimate the probability of target attainment (PTA) of therapeutic concentrations under various dosing regimens across different aspartate aminotransferase (AST) stratifications, with the aim of identifying optimal dosing strategies.
resultsThis prospective study enrolled 30 critically ill adult patients receiving ECMO support, from whom a total of 183 VRC plasma concentration were obtained. VRC PK was adequately described by a two-compartment model. AST was identified as a significant covariate influencing VRC clearance. Model evaluation demonstrated that the final model exhibited robust stability and predictive performance. MCS results indicated that patients with AST levels > 65 U/L could achieve the therapeutic target range of VRC trough concentrations with lower loading and maintenance doses.
conclusionsThis study provides quantitative evidence to support the optimization of VRC dosing in critically ill adult patients receiving ECMO support. The findings may improve the precision of individualized antifungal therapy and serve as a reference for the development of future dosing strategies in this population.
Indexed as
Identifiers
41826587What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.